AIMS: The aim of this study was to compare outcomes with the use of two haemostasis strategies after transfemoral transcatheter aortic valve implantation (TAVI) - one Prostar® vs. two ProGlide® devices (Abbott Vascular Inc., Santa Clara, CA, USA). METHODS AND RESULTS: This was a retrospective study enrolling consecutive patients undergoing fully percutaneous transfemoral TAVI in our centre (Ferrarotto Hospital, Catania, Italy) from January 2012 to October 2014. All patients were dichotomised according to the vascular closure device (VCD) used for common femoral artery haemostasis (Prostar vs. ProGlide). All outcomes were defined according to VARC-2 criteria. The study population encompassed a total of 278 patients. Of these, 153 (55.1%) underwent TAVI using the Prostar, and 125 (44.9%) using two ProGlide devices. Vascular complications occurred in 48 patients (17.3%), being more frequent in the ProGlide group (11.8% vs. 24.0%, p=0.007). Patients who had TAVI using the ProGlide were also more likely to have a higher rate of percutaneous closure device failure (4.6% vs. 12.8%, p=0.013). Percutaneous peripheral intervention was performed in 13.7% and 28.0% of Prostar and ProGlide cases, respectively (p=0.003). CONCLUSIONS: Patients undergoing transfemoral TAVI had significantly lower rates of vascular complications and percutaneous closure device failures when the Prostar was used compared with two ProGlide devices.
AIMS: The aim of this study was to compare outcomes with the use of two haemostasis strategies after transfemoral transcatheter aortic valve implantation (TAVI) - one Prostar® vs. two ProGlide® devices (Abbott Vascular Inc., Santa Clara, CA, USA). METHODS AND RESULTS: This was a retrospective study enrolling consecutive patients undergoing fully percutaneous transfemoral TAVI in our centre (Ferrarotto Hospital, Catania, Italy) from January 2012 to October 2014. All patients were dichotomised according to the vascular closure device (VCD) used for common femoral artery haemostasis (Prostar vs. ProGlide). All outcomes were defined according to VARC-2 criteria. The study population encompassed a total of 278 patients. Of these, 153 (55.1%) underwent TAVI using the Prostar, and 125 (44.9%) using two ProGlide devices. Vascular complications occurred in 48 patients (17.3%), being more frequent in the ProGlide group (11.8% vs. 24.0%, p=0.007). Patients who had TAVI using the ProGlide were also more likely to have a higher rate of percutaneous closure device failure (4.6% vs. 12.8%, p=0.013). Percutaneous peripheral intervention was performed in 13.7% and 28.0% of Prostar and ProGlide cases, respectively (p=0.003). CONCLUSIONS:Patients undergoing transfemoral TAVI had significantly lower rates of vascular complications and percutaneous closure device failures when the Prostar was used compared with two ProGlide devices.
Authors: Luise Gaede; Johannes Blumenstein; Christoph Liebetrau; Oliver Dörr; Won-Keun Kim; Holger Nef; Oliver Husser; Jan Gülker; Albrecht Elsässer; Christian W Hamm; Stephan Achenbach; Helge Möllmann Journal: Clin Res Cardiol Date: 2019-06-24 Impact factor: 5.460
Authors: Herbert G Kroon; Pim A L Tonino; Mikko Savontaus; Giovanni Amoroso; Mika Laine; Evald H Christiansen; Stefan Toggweiler; Jur Ten Berg; Janarthanan Sathananthan; Joost Daemen; Peter P de Jaegere; Guus B R G Brueren; Markus Malmberg; Ton Slagboom; Noriaki Moriyama; Christian J Terkelsen; Federico Moccetti; Livia Gheorghe; John Webb; David Wood; Nicolas M Van Mieghem Journal: Catheter Cardiovasc Interv Date: 2020-12-21 Impact factor: 2.692
Authors: Maarten P van Wiechen; Herbert Kroon; Thijmen W Hokken; Joris F Ooms; Marjo J de Ronde-Tillmans; Joost Daemen; Peter P de Jaegere; Nicolas M Van Mieghem Journal: Catheter Cardiovasc Interv Date: 2021-02-03 Impact factor: 2.585
Authors: Radosław Parma; Maciej Dąbrowski; Andrzej Ochała; Adam Witkowski; Dariusz Dudek; Zbigniew Siudak; Jacek Legutko Journal: Postepy Kardiol Interwencyjnej Date: 2017-03-10 Impact factor: 1.426
Authors: Gregor Heitzinger; Christina Brunner; Sophia Koschatko; Varius Dannenberg; Katharina Mascherbauer; Kseniya Halavina; Carolina Doná; Matthias Koschutnik; Georg Spinka; Christian Nitsche; Markus Mach; Martin Andreas; Florian Wolf; Christian Loewe; Christoph Neumayer; Michael Gschwandtner; Andrea Willfort-Ehringer; Max-Paul Winter; Irene M Lang; Philipp E Bartko; Christian Hengstenberg; Georg Goliasch Journal: Front Cardiovasc Med Date: 2022-01-21
Authors: Claudio Montalto; Andrea Raffaele Munafò; Luca Arzuffi; Francesco Soriano; Antonio Mangieri; Stefano Nava; Giovanni Luigi De Maria; Francesco Burzotta; Fabrizio D'Ascenzo; Antonio Colombo; Azeem Latib; Jacopo Andrea Oreglia; Adrian P Banning; Italo Porto; Gabriele Crimi Journal: Eur Heart J Open Date: 2022-08-18
Authors: Sergio Berti; Francesco Bedogni; Arturo Giordano; Anna S Petronio; Alessandro Iadanza; Antonio L Bartorelli; Bernard Reimers; Carmen Spaccarotella; Carlo Trani; Tiziana Attisano; Angela Marella Cenname; Gennaro Sardella; Roberto Bonmassari; Massimo Medda; Fabrizio Tomai; Giuseppe Tarantini; Eliano P Navarese Journal: J Am Heart Assoc Date: 2020-10-24 Impact factor: 5.501